SWEDEN: REMYNIL BY SANOCHEMIA

Article Abstract:

The Austrian company Sanochemia Pharmazeutika AG is to file for European approval for Remynil. The pharmaceutical for the treatment of Alzheimer's disease, which contains galantamine, has been approved in Sweden. Sanochemia's partners, Janssen-Cilag and Shire Pharmaceuticals Group plc will market the drug worldwide.

Government regulation (cont), European Union, Sweden

---

SWITZERLAND/UK: ARES SERONO, BRITISH BIOTECH R&D

Article Abstract:

Ares Serono of Switzerland and British Biotech plc of Oxford have signed an exclusive cooperation agreement concerning research, development and commercialisation of metal enzyme inhibitors for the treatment of severe inflammatory diseases. British Biotech is starting clinical tests of two inhibitors. Ares Serono has secured an option for the exclusive rights to the two inhibitors, which might be used in the treatment of multiple sclerosis.

Drugs & Pharmaceuticals, Biochemistry, Pharmaceutical and Medicine Manufacturing, Research and Development in the Physical, Engineering, and Life Sciences, Research & development outlays, Drugs, Enzymes, Other Basic Organic Chemical Manufacturing, Central Nervous System Prep, Central nervous system agents

---

AUSTRIA: SANOCHEMIA BOOSTS SYNTHESIS

Article Abstract:

The Austrian company Sanochemia Pharmazeutika is quadrupling active agent synthesis capacity at its plant in Neufeld to 12 tonnes per year. The investment amounts to EUR 2.9mn. The facility is used also for the production of the Alzheimer treatment Nivalin.

New capacity, new plant construction

Similar abstracts:

• Abstracts: GERMANY: MERCK CLOSES THIOGLYCOL ACID FACILITY. GERMANY: TARTARIC ACID FROM LEUNA. GERMANY: AKZO NOBEL TENSIDES TO HANSA CHEMIE

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.